Baidu
map

FDA批准Lampit(nifurtimox)用于治疗儿童恰加斯病

2020-08-09 Allan MedSci原创

恰加斯病又称为南美锥虫病,是一种热带疾病寄生虫病。致病原是克氏锥虫,通常借由俗称为亲吻虫的锥鼻虫传播。

恰加斯病又称为南美锥虫病,是一种热带疾病寄生虫病。致病原是克氏锥虫,通常借由俗称为亲吻虫的锥鼻虫传播。感染的症状随着疾病的进程而改变。在感染初期,以下症状的表征严重度不一:发烧、淋巴结肿大、头痛或是被叮咬位置的局部肿大。叮咬后8到12周,疾病进入慢性期,60%到70%不再出现新症状。其他30%到40%的人,在初次感染后的10到30年间,会出现更多症状。这些症状包括心室扩大,其中20到30%甚至会导致心脏衰竭。在美国约有30万人受感染。据估计700-800万人感染恰加斯病,大多位于墨西哥、中美洲与南美洲。2006年,此病共造成约12,500人死亡。

拜耳制药近日宣布,美国食品药品监督管理局(FDA)已批准Lampit®(nifurtimox)用于治疗儿童恰加斯病。Lampit是一种抗原生动物药物,根据处方说明,该片剂可专门配制以分散在水中,可帮助可能难以吞咽整片或半片片剂的小儿患者服药。

该适应症是在加速批准背景下获得批准的。拜耳公司美洲区高级副总裁兼医学事务负责人Aleksandra Vlajnic博士说:“恰加斯病可以在任何年龄发生,并且早期发现和治疗很重要,因此,在儿童时期就进行治疗对于降低恰加斯病带来的风险就尤为重要”。

 

原始出处:

https://www.firstwordpharma.com/node/1747522?tsid=4

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1839862, encodeId=baec1839862d3, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Mon Oct 05 02:31:03 CST 2020, time=2020-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1953316, encodeId=e1ac195331667, content=<a href='/topic/show?id=ed1d528e71b' target=_blank style='color:#2F92EE;'>#恰加斯病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52877, encryptionId=ed1d528e71b, topicName=恰加斯病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2b9b368, createdName=qingrejiedu, createdTime=Mon Jan 11 15:31:03 CST 2021, time=2021-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2057687, encodeId=b929205e687e2, content=<a href='/topic/show?id=c02b106e29a' target=_blank style='color:#2F92EE;'>#LAM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10672, encryptionId=c02b106e29a, topicName=LAM)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04ce158, createdName=lxg951, createdTime=Tue Oct 27 13:31:03 CST 2020, time=2020-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=807082, encodeId=d7c780e082cc, content=厉害, beContent=null, objectType=article, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ebec5386904, createdName=长毛小米, createdTime=Sun Aug 09 11:38:43 CST 2020, time=2020-08-09, status=1, ipAttribution=)]
    2020-10-05 bugit
  2. [GetPortalCommentsPageByObjectIdResponse(id=1839862, encodeId=baec1839862d3, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Mon Oct 05 02:31:03 CST 2020, time=2020-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1953316, encodeId=e1ac195331667, content=<a href='/topic/show?id=ed1d528e71b' target=_blank style='color:#2F92EE;'>#恰加斯病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52877, encryptionId=ed1d528e71b, topicName=恰加斯病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2b9b368, createdName=qingrejiedu, createdTime=Mon Jan 11 15:31:03 CST 2021, time=2021-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2057687, encodeId=b929205e687e2, content=<a href='/topic/show?id=c02b106e29a' target=_blank style='color:#2F92EE;'>#LAM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10672, encryptionId=c02b106e29a, topicName=LAM)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04ce158, createdName=lxg951, createdTime=Tue Oct 27 13:31:03 CST 2020, time=2020-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=807082, encodeId=d7c780e082cc, content=厉害, beContent=null, objectType=article, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ebec5386904, createdName=长毛小米, createdTime=Sun Aug 09 11:38:43 CST 2020, time=2020-08-09, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1839862, encodeId=baec1839862d3, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Mon Oct 05 02:31:03 CST 2020, time=2020-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1953316, encodeId=e1ac195331667, content=<a href='/topic/show?id=ed1d528e71b' target=_blank style='color:#2F92EE;'>#恰加斯病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52877, encryptionId=ed1d528e71b, topicName=恰加斯病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2b9b368, createdName=qingrejiedu, createdTime=Mon Jan 11 15:31:03 CST 2021, time=2021-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2057687, encodeId=b929205e687e2, content=<a href='/topic/show?id=c02b106e29a' target=_blank style='color:#2F92EE;'>#LAM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10672, encryptionId=c02b106e29a, topicName=LAM)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04ce158, createdName=lxg951, createdTime=Tue Oct 27 13:31:03 CST 2020, time=2020-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=807082, encodeId=d7c780e082cc, content=厉害, beContent=null, objectType=article, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ebec5386904, createdName=长毛小米, createdTime=Sun Aug 09 11:38:43 CST 2020, time=2020-08-09, status=1, ipAttribution=)]
    2020-10-27 lxg951
  4. [GetPortalCommentsPageByObjectIdResponse(id=1839862, encodeId=baec1839862d3, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Mon Oct 05 02:31:03 CST 2020, time=2020-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1953316, encodeId=e1ac195331667, content=<a href='/topic/show?id=ed1d528e71b' target=_blank style='color:#2F92EE;'>#恰加斯病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52877, encryptionId=ed1d528e71b, topicName=恰加斯病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2b9b368, createdName=qingrejiedu, createdTime=Mon Jan 11 15:31:03 CST 2021, time=2021-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2057687, encodeId=b929205e687e2, content=<a href='/topic/show?id=c02b106e29a' target=_blank style='color:#2F92EE;'>#LAM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10672, encryptionId=c02b106e29a, topicName=LAM)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04ce158, createdName=lxg951, createdTime=Tue Oct 27 13:31:03 CST 2020, time=2020-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=807082, encodeId=d7c780e082cc, content=厉害, beContent=null, objectType=article, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ebec5386904, createdName=长毛小米, createdTime=Sun Aug 09 11:38:43 CST 2020, time=2020-08-09, status=1, ipAttribution=)]
    2020-08-09 长毛小米

    厉害

    0

相关资讯

FDA批准美国恰加斯病治疗药物

美国食品和药物管理局(FDA)已经加速批准苄硝唑用于治疗患有恰加斯病的2~12岁儿童,成为美国批准用于这种罕见病的首个治疗方法。

拓展阅读

FDA批准美国恰加斯病治疗药物

美国食品和药物管理局(FDA)已经加速批准苄硝唑用于治疗患有恰加斯病的2~12岁儿童,成为美国批准用于这种罕见病的首个治疗方法。

Baidu
map
Baidu
map
Baidu
map